Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.45 |
| ▸ | PLK1 | P53350 | 4/20 | 0.44 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.44 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1926346 | 0.88 | PLK1 (0.51) | PLK1LRRK2 | |
| SCHEMBL1926244 | 0.88 | PLK1 (0.49) | USP30PTK2PLK1PLK3PLK2 | |
| SCHEMBL1925997 | 0.86 | PLK1 (0.48) | USP30PTK2PLK1PLK3PLK2 | |
| SCHEMBL1927973 | 0.85 | USP30 (0.50) | USP30PTK2PLK1PLK3PLK2 | |
| SCHEMBL1927285 | 0.84 | PLK1 (0.50) | USP30PTK2PLK1PLK3PLK2 | |
| SCHEMBL1926562 | 0.82 | USP30 (0.53) | USP30PTK2PLK1PLK3PLK2 | |
| SCHEMBL1926343 | 0.82 | USP30 (0.49) | USP30PTK2PLK1PLK3PLK2 | |
| SCHEMBL1927087 | 0.82 | PLK1 (0.48) | USP30PTK2PLK1PLK3PLK2 | |
| SCHEMBL1927238 | 0.82 | USP30 (0.51) | USP30PTK2PLK1PLK3PLK2 | |
| SCHEMBL1927232 | 0.81 | PLK1 (0.51) | USP30PTK2PLK1PLK3PLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956185-B2 | Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases | ABBOTT LABORATORIES (US) | 2011-06-07 | — | — | US | claimed |
| US-7956185-B2 | Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases | ABBOTT LABORATORIES (US) | 2011-06-07 | — | — | US | disclosed |
| US-20080015192-A1 | INHIBITORS OF POLO-LIKE KINASES | ABBVIE INC. | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015192-A1 | INHIBITORS OF POLO-LIKE KINASES | PLK1, PLK2, BUB1B | USP30 2177/4885PTK2 348/4885PLK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.